Trial Profile
A Phase II Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bermekimab (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Janssen Research & Development; XBiotech
- 07 Jul 2015 Results published in the media release.
- 07 Jul 2015 Results published online in the Journal of Diabetes and its Complications, according to an XBiotech media release.
- 30 Oct 2012 Interim efficacy results reported in a XBiotech media release.